Argenta expands collaboration with Genentech to include BioFocus

14-Sep-2010 - United Kingdom

Argenta, a service division of Galapagos NV, announced it has signed a contract extension with Genentech, Inc., a member of the Roche Group. The extended agreement expands the portfolio of projects which are in collaboration with Genentech and allows Genentech to place projects directly into Galapagos’ other service division, BioFocus.

Argenta’s collaboration with Genentech dates back to 2005. The current agreement covers a number of drug discovery programs that utilize Argenta's expertise in computer-aided drug design (CADD), medicinal chemistry, and in vitro biology and screening to discover new chemical entities acting against undisclosed drug targets defined by Genentech. Under the amendment announced today, BioFocus will provide Genentech with integrated medicinal chemistry, in vitro biology and ADME services.

“We are delighted that Genentech has expanded its small-molecule drug discovery outsourcing into BioFocus, and we regard it as testament to the complementary expertise and technological capabilities that Argenta and BioFocus possess,” said Chris Newton, Senior Vice President, Galapagos Services.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances